Summit Therapeutics stock is trading -40.58% below its average target price of $30.43 after marking a 5.4% during today's evening session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $12.115718 to $45.02597 per share.
The stock has an unusually large proportion of its shares sold short at 25.6%, and a short ratio of 13.27. The company's insiders own 82.64% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a very small number of institutional investors are invested in the stock, with 15.8% of Summit Therapeutics's shares being owned by this investor type.
Institutions Invested in Summit Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-12-31 | Baker Bros. Advisors, LP | 5% | 36,391,063 | $657,950,416 |
| 2025-12-31 | FMR, LLC | 2% | 13,360,807 | $241,563,389 |
| 2025-12-31 | Vanguard Group Inc | 1% | 11,177,220 | $202,084,136 |
| 2025-12-31 | Blackrock Inc. | 1% | 9,361,921 | $169,263,530 |
| 2025-12-31 | Price (T.Rowe) Associates Inc | 1% | 9,371,415 | $169,435,182 |
| 2025-12-31 | State Street Corporation | 1% | 6,636,361 | $119,985,406 |
| 2026-03-31 | UBS Group AG | 0% | 3,680,315 | $66,540,094 |
| 2025-12-31 | Geode Capital Management, LLC | 0% | 3,147,480 | $56,906,438 |
| 2025-12-31 | Citadel Advisors Llc | 0% | 2,475,708 | $44,760,800 |
| 2025-12-31 | Polymer Capital Management (HK) Ltd | 0% | 1,421,155 | $25,694,482 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Summit Therapeutics.
